Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

Biogen said it has paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drug specialist it bought for $5.6 billion earlier this year. The move signals a post-acquisition rationalization of R&D spending and could weigh on Apellis-associated development activity. The announcement is important for the combined company but is unlikely to be broadly market-moving.

Analysis

Biogen said it has paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drug specialist it bought for $5.6 billion earlier this year. The move signals a post-acquisition rationalization of R&D spending and could weigh on Apellis-associated development activity. The announcement is important for the combined company but is unlikely to be broadly market-moving.